Welcome to volume 18 of Nanomedicine

We are excited to welcome all our readers to the new volume of Nanomedicine. In 2022, we were delighted to serve a global audience with the latest developments in nanomedicine, as our articles were read in over 180 territories. Another, more personal, highlight for the journal was my takeover of editorial responsibilities beginning in August 2022.

Read on to learn about some of the most impactful content from 2022 by readers and citations.

Content highlights for 2022

In our 17th volume, we published articles covering a range of topics. While our work on COVID-19 continues to receive attention and citations, most of our new submissions relate to applications of nanomedicine in other diseases, ranging from oncology to the treatment of HIV. This highlights the breadth of research adopting nanomedicines and its potential to be a key approach to combat diseases.

Our 2022 volume included its first ever Plain Language Summary of Publication. This standalone piece from Savinova et al. summarizes research published in an earlier edition of Nanomedicine on the potential for Raman spectroscopy to monitor blood cancer for a nonspecialist audience, in a way that is easily interpretable by researchers and clinicians from different disciplines and patients alike [1]. If you would be interested in publishing a Plain Language Summary of Publication in Nanomedicine, please visit the corresponding website [2].

Table 1 shows our most cited content published in 2021 and 2022. Our two most cited articles in this period come from nanomedicines for oncology applications. The top article was a Commentary from Wei et al. that explored the need for novel anticancer nanomedicines to sequentially respond to stimuli to improve site specific drug-delivery efficacy [3]. The second ranked article was by Jiang et al., which reviewed the increasing body of research on copper complexes antitumor mechanisms [4]. All our articles are accompanied by information on citations from Dimensions [5].

The most read opinion article published in 2022, and a personal favorite of mine, was a Commentary by B Nelson and SE Borgos, with 3219 readers accessing their piece. The article recommends steps to increase the speed of development of next-generation nucleic acid lipid nanoparticles. Table 2 summarizes our most read articles published in volume 17 of Nanomedicine.

Author & reader geographic spread

In addition to the subject matter for our articles, we consider where our readers and contributors are based. In 2022, the top three countries by access for Nanomedicine were China, the USA and India. When considering the data by continent, over half our content access was from Asia with 57%, as seen in Figure 1.

Our accepted manuscripts also come from across the globe. Figure 2 shows the geographical distribution of accepted manuscripts as measured by the corresponding author. Asia once again dominated, with India and China the top two countries by accepted manuscript, with the USA third.

Special focus issue

In May 2022, we published a special focus issue titled, ‘Targeted drug delivery for inflammatory lung diseases’ with guest editors K Dua, D Chellappan and R Löbenberg. This issue explored inflammation associated with common chronic respiratory diseases and the need for novel drug-delivery systems to treat this [14]. The articles included intriguing research from Van Bavel et al., who explored the impact of vaping additives on model lung surfactants to assess their potential impact on e-cigarette, or vaping, product use-associated lung injury [15]. This was followed up by the publication of a related series of four themed issues in November and December. We would like to express our gratitude to our guest editors for their help in compiling these.

Conclusion

We would like to thank all the authors, reviewers and readers of Nanomedicine who have contributed to the past volume. I would particularly like to thank the editorial board for their kind welcome and support over the past year.

Nanomedicine can be found on Twitter at @fsgnnm, where we share research published in our journal with our growing number of followers. We also have a LinkedIn group ‘Nanomedicine (London)’ [16] for contributors and others interested in the journal that we would be delighted for our contributors and readers to join and engage.

Nanomedicine gladly considers unsolicited articles of all types. If you are interested in contributing or wish to offer feedback on the journal, please reach out via email or via our Twitter direct messages on @fsgnnm.